S9704-S0014-S0313A Studying Genes in Samples From Patients With Limited or Advanced Diffuse Large B-Cell Lymphoma
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01563861|
Recruitment Status : Completed
First Posted : March 27, 2012
Last Update Posted : December 21, 2017
RATIONALE: Studying samples of tumor tissue from patients with cancer in the laboratory may help doctors identify and learn more about biomarkers related to cancer. It may also help doctors find better ways to treat cancer.
PURPOSE: This research trial studies genes in samples from patients with limited and advanced diffuse large B-cell lymphoma.
|Condition or disease||Intervention/treatment|
|Lymphoma||Genetic: RNA analysis Genetic: gene expression analysis Other: immunohistochemistry staining method Other: laboratory biomarker analysis|
- To determine the proportion of the cell of origin subtypes (germinal center B-cell-like [GCB] vs non-GCB) and expression levels of prognostic genes previously identified in diffuse large B-cell lymphoma (DLBCL) in patient biopsy samples from SWOG trials of limited- and advanced-stage DLBCL, and to assess the association between the results and progression-free survival (PFS).
- To assess the association between these marker results and overall survival (OS).
OUTLINE: Archived formalin-fixed paraffin-embedded tissue are analyzed for gene expression profile by quantitative nuclease protection assay (qNPA) and immunohistochemical analyses. Results are then compared with each patient's progression-free survival and overall survival.
|Study Type :||Observational|
|Actual Enrollment :||397 participants|
|Official Title:||Determining the Cell of Origin and Prognostic Gene Signatures in SWOG Trials of Diffuse Large B-Cell Lymphoma|
|Study Start Date :||February 2012|
|Primary Completion Date :||March 2012|
|Study Completion Date :||March 2012|
- Proportion of GCB phenotype among limited-stage vs advanced-stage patients [ Time Frame: Retrospectively ]
- Differences in PFS between limited- and advanced-stage patients with the GCB and non-GCB phenotypes [ Time Frame: Retrospectively ]
- Association between GCB markers and OS [ Time Frame: Retrospectively ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01563861
|Principal Investigator:||Daniel O. Persky, MD||University of Arizona|